| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Effect of exchange rate changes on cash | 29 | - |
| Net loss | -8,423 | -5,223 |
| Depreciation | 23 | 15 |
| Share-based compensation | 2,040 | 1,113 |
| The amount of finance income (expenses), net | 8 | - |
| Increase in other current assets | 219 | 252 |
| Decrease (increase) in accounts receivable | -126 | -126 |
| Increase (decrease) in accounts payable | 84 | 251 |
| The amount of finance expenses, net | - | 18 |
| Increase (decrease) in accrued liabilities and other operating liabilities | 840 | 917 |
| Net cash provided by (used in) operating activities | -5,537 | -3,035 |
| Purchase of property and equipment | 80 | 37 |
| Net cash provided by (used in) investing activities | -80 | -37 |
| Proceeds from issuance of common stock | 6,254 | 6,183 |
| The amount represents proceeds from issuance of shares under collaboration agreement | 7,190 | 7,190 |
| Issuance cost | 262 | 261 |
| Proceeds from warrant exercises | 354 | 174 |
| Net cash provided by (used in) financing activities | 13,536 | 13,286 |
| Cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), excluding exchange rate effect, including discontinued operation | 7,919 | - |
| Cash and cash equivalents at beginning of period | 8,740 | - |
| Cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect | - | 10,214 |
| Cash and cash equivalents at end of period | 16,688 | - |
Entera Bio Ltd. (ENTXW)
Entera Bio Ltd. (ENTXW)